Direkt zum Inhalt
Merck

Management of epidermolysis bullosa acquisita.

Dermatologic clinics (2011-09-20)
Lizbeth R A Intong, Dédée F Murrell
ZUSAMMENFASSUNG

Epidermolysis bullosa acquisita is a rare and debilitating autoimmune mucocutaneous blistering disease caused by autoantibodies directed against type VII collagen or anchoring fibrils in the subepidermal basement membrane zone. Treatment is quite challenging because this disease can be recalcitrant to multiple modalities. This article discusses the current management of this disease.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Sulfapyridin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Sulfapyridin, ≥99.0%
Supelco
Sulfapyridin, VETRANAL®, analytical standard